Sonja Schönecker,Francisco J Martinez-Murcia,Jannis Denecke,Nicolai Franzmeier,Adrian Danek,Olivia Wagemann,Catharina Prix,Elisabeth Wlasich,Jonathan Vöglein,Sandra V Loosli,Anna Brauer,Juan-Manuel Górriz Sáez,Arabella Bouzigues,Lucy L Russell,Phoebe H Foster,Eve Ferry-Bolder,John C van Swieten,Lize C Jiskoot,Harro Seelaar,Raquel Sanchez-Valle,Robert Laforce Jr,Caroline Graff,Daniela Galimberti,Rik Vandenberghe,Alexandre de Mendonça,Pietro Tiraboschi,Isabel Santana,Alexander Gerhard,Sandro Sorbi,Markus Otto,Florence Pasquier,Simon Ducharme,Christopher Butler,Isabelle Le Ber,Elizabeth Finger,Maria Carmela Tartaglia,Mario Masellis,James B Rowe,Matthis Synofzik,Fermin Moreno,Barbara Borroni,Jonathan D Rohrer,Genetic Frontotemporal Dementia Initiative (GENFI),Josef Priller,Günter U Höglinger,Johannes Levin

Abstract:Background and objectives: Behavioral and neuropsychiatric symptoms are frequent in patients with genetic frontotemporal dementia (FTD). We aimed to describe behavioral and neuropsychiatric phenotypes in genetic FTD, quantify their temporal association, and investigate their regional association with brain atrophy. Methods: We analyzed data of pathogenic variant carriers in the chromosome 9 open reading frame 72 (c9orf72), progranulin (GRN), or microtubule-associated protein tau (MAPT) gene from the Genetic Frontotemporal dementia Initiative cohort study that enrolls both symptomatic pathogenic variant carriers and first-degree relatives of known carriers. Principal component analysis was performed to identify behavioral and neuropsychiatric clusters that were compared with respect to frequency and severity between groups. Associations between neuropsychiatric clusters and MRI-assessed atrophy were determined using voxel-based morphometry. We applied linear mixed effects and generalized linear mixed effects models to assess the longitudinal course of symptoms. Results: A total of 522 participants were included: 221 c9orf72 (138 presymptomatic), 213 GRN (157 presymptomatic), and 88 MAPT (62 presymptomatic) pathogenic variant carriers. Principal component analysis revealed 5 phenotypic clusters (67.6% of variance), labeled diverse behavioral, affective, psychotic, euphoric/hypersexual, and tactile hallucinations phenotype. In participants presenting behavioral or neuropsychiatric symptoms, affective symptoms were most frequent across groups (83.6%-88.1%), followed by diverse behavioral symptoms (68.4%-77.9%). In c9orf72 and GRN pathogenic variant carriers, psychotic symptoms (32.0% and 19.4%, respectively) were more frequent than euphoric/hypersexual symptoms (28.7% and 14.2%, respectively), which was the other way around in MAPT pathogenic variant carriers (28.6% and 23.8%). Although diverse behavioral symptoms were associated with gray and white matter frontotemporal atrophy, only a small atrophy cluster in the right thalamus was associated with psychotic symptoms. Euphoric/hypersexual symptoms were associated with atrophy in mesial temporal lobes, basal forebrain structures, and the striatum (p < 0.05). Estimated time to symptom onset, genetic group, education, and sex influenced behavioral and neuropsychiatric symptoms (p < 0.05). Particularly, in c9orf72 pathogenic variant carriers, psychotic symptoms may be starting decades before recognition of onset of illness. Discussion: We identified multiple clusters of behavioral and neuropsychiatric symptoms in participants with genetic FTD that relate to distinct cerebral atrophy patterns. Their severity depends on time, affected gene, sex, and education. These clinical-genetic associations can guide diagnostic evaluations and the design of clinical trials for new disease-modifying and preventive treatments.

Frontoparietal network integrity supports cognitive function in pre‐symptomatic frontotemporal dementia: Multimodal analysis of brain function, structure, and perfusion

Frontoparietal network integrity supports cognitive function despite atrophy and hypoperfusion in pre-symptomatic frontotemporal dementia: multimodal analysis of brain function, structure and perfusion

Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results

Structural MRI predicts clinical progression in presymptomatic genetic frontotemporal dementia: findings from the GENetic Frontotemporal dementia Initiative cohort

Brain volumetric deficits in MAPT mutation carriers: a multisite study

Impaired glymphatic system in genetic frontotemporal dementia: a GENFI study

Executive function deficits in genetic frontotemporal dementia: results from the GENFI study

Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study

Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia

Reconfigured metabolism brain network in asymptomatic microtubule-associated protein tau mutation carriers: a graph theoretical analysis

Frequency and Longitudinal Course of Behavioral and Neuropsychiatric Symptoms in Participants With Genetic Frontotemporal Dementia

Inflammatory plasma profile in genetic symptomatic and presymptomatic Frontotemporal Dementia - A GENFI study

Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort

Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease

Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β-amyloid, Tau, and APOE4

Detecting cognitive decline in high-functioning older adults: The relationship between subjective cognitive concerns, frequency of high neuropsychological test scores, and the frontoparietal control network

Left Frontoparietal Connectivity Counteracts Locus Coeruleus‐Related Attentional Decline in Preclinical Alzheimer’s Disease

Stronger Bilateral Functional Connectivity of the Frontoparietal Control Network in Near-Centenarians and Centenarians Without Dementia.

Prodromal language impairment in genetic frontotemporal dementia within the GENFI cohort

Longitudinal resting-state functional connectivity and regional brain atrophy-based biomarkers of preclinical cognitive impairment in healthy old adults

Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage